March 30, 2026
Nexsen Limited (ASX:NXN) sets parallel pathway to early revenue and U.S. submission for StrepSure®
Mark Muzzin outlines Nexsen’s pathway to early revenue and U.S. submission for StrepSure®
Category: Biotech
February 3, 2026
Argenica Therapeutics (ASX:AGN) secures EMA paediatric waiver, simplifying European approval pathway for lead stroke asset
Dr Liz Dallimore, Managing Director of Argenica Therapeutics, explains why securing an EMA paediatric waiver for ARG-007 materially simplifies the European approval pathway and tightens execution around the company’s adult stroke program.
October 28, 2025
Arovella Therapeutics (ASX:ALA) showcases progress in next-generation iNKT cell therapy at AusBiotech Invest 2025
Arovella Therapeutics (ASX:ALA) has presented its progress toward clinical trials for its lead iNKT cell therapy ALA-101, showcasing its next-generation cancer treatment platform at AusBiotech Invest 2025.
November 19, 2024
BlinkLab (ASX:BB1) AI diagnostic revolution: A new era in autism detection
BlinkLab’s smartphone-based diagnostic test, BlinkLab Dx 1, is revolutionising autism detection with 91% sensitivity and 85% specificity, offering a faster, scalable, and more equitable alternative to traditional methods
August 26, 2024
Tryptamine Therapeutics (ASX:TYP) completes pivotal Phase 1b trial for psilocin-based therapy
Tryptamine Therapeutics has successfully completed its Phase 1b trial for TRP-8803, marking a significant step forward in the development of its innovative psilocin-based therapy.
December 14, 2023
Argenica (ASX:AGN) mark the manufacturing milestone for clinical trials
A manufacturing milestone paves the way to begin Phase 2 clinical trials and towards pivotal Phase 3 and potential partnerships.
June 6, 2023
Memphasys (ASX: MEM) leads the pack in sperm separation
Study shows FelixTM System offers significant advantages over alternative sperm
separation techniques on cryopreserved semen.